The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.
The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Abstract
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7)”
From Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test (2021) · cites this paper as [7]
In the citing paper
“dysregulated α-cell release of glucagon, manifest as increased fasting glucagon concentrations and a failure to adequately suppress glucagon release following meal ingestion, contributes to the development of hyperglycaemia34.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [34]
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Research works printed but not linked: 9
- 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
- 2005, Byetta (exenatide injection)[prescribing information].
- Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
- Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
- Balas, J Clin Endocrinol Metab
- Dejager, Horm Metab Res
- Bosi, Diabetes Care
- Rosenstock, Diabetes Obes Metab
- Garber, Diabetes Obes Metab
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A. H., Kirkpatrick, C. L., Wollheim, C. B., Eliasson, L., Rönn, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004160 · Cited by 523
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., & Wondisford, F. E. (2009) · Cell · doi:10.1016/j.cell.2009.03.016 · Cited by 481
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 458
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes
Quesada, I., Tudurí, E., Ripoll, C., & Nadal, Á. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0290 · Cited by 412
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
The Cells of the Islets of Langerhans
Da Silva Xavier, G. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030054 · Cited by 295
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
“Multiple studies demonstrate that GLP-1R agonists and DPP-4 inhibitors inhibit glucagon secretion (2,27).”
BackgroundFærch, K., Borch-Johnsen, K., Holst, J. J., & Vaag, A. (2009) · Diabetologia · doi:10.1007/s00125-009-1443-3 · Cited by 252
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
The role of dysregulated glucagon secretion in type 2 diabetes
D'Alessio, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01449.x · Cited by 238
“While the normal α-cell response to oral glucose ingestion is a mild reduction of secretion, mixed nutrient meals stimulate increases in plasma glucagon [2,27].”
BackgroundInfluentialKomiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151511 · Cited by 228
The role of FOXO1 in β-cell failure and type 2 diabetes mellitus
Kitamura, T. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.157 · Cited by 221
Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1643 · Cited by 212
Seck, T., Nauck, M., Sheng, D., Sunga, S., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & for the Sitagliptin Study 024 Group (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02353.x · Cited by 208
Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia
Longuet, C., Robledo, A. M., Dean, E. D., Dai, C., Ali, S., McGuinness, I., de Chavez, V., Vuguin, P. M., Charron, M. J., Powers, A. C., et al. (2013) · Diabetes · doi:10.2337/db11-1605 · Cited by 206
Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy
Yang, H., & Yang, L. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0316 · Cited by 203
MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes
Ardestani, A., Paroni, F., Azizi, Z., Kaur, S., Khobragade, V., Yuan, T., Frogne, T., Tao, W., Oberholzer, J., Pattou, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3482 · Cited by 200
Update on otitis media – prevention and treatment
Daniel, M., Qureishi, A., Lee, Y., Belfield, K., & Birchall, J. (2014) · Infection and Drug Resistance · doi:10.2147/idr.s39637 · Cited by 189
Pancreatic alpha cell mass in European subjects with type 2 diabetes
Henquin, J. C., & Rahier, J. (2011) · Diabetologia · doi:10.1007/s00125-011-2118-4 · Cited by 185
Ahrén, B., Schweizer, A., Dejager, S., Dunning, B. E., Nilsson, P. M., Persson, M., & Foley, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2152 · Cited by 183
Self-citationLoss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits
Spijker, H. S., Song, H., Ellenbroek, J. H., Roefs, M. M., Engelse, M. A., Bos, E., Koster, A. J., Rabelink, T. J., Hansen, B. C., Clark, A., et al. (2015) · Diabetes · doi:10.2337/db14-1752 · Cited by 172
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
Borse, S., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2020) · Medical Principles and Practice · doi:10.1159/000511002 · Cited by 172
Evidence of Extrapancreatic Glucagon Secretion in Man
Lund, A., Bagger, J. I., Wewer Albrechtsen, N. J., Christensen, M., Grøndahl, M., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., et al. (2016) · Diabetes · doi:10.2337/db15-1541 · Cited by 168
Guardado-Mendoza, R., Davalli, A. M., Chavez, A. O., Hubbard, G. B., Dick, E. J., Majluf-Cruz, A., Tene-Perez, C. E., Goldschmidt, L., Hart, J., Perego, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906471106 · Cited by 166
GPR119 agonists for the treatment of type 2 diabetes
Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903153878 · Cited by 164
Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling
Matveyenko, A. V., Liuwantara, D., Gurlo, T., Kirakossian, D., Dalla Man, C., Cobelli, C., White, M. F., Copps, K. D., Volpi, E., Fujita, S., et al. (2012) · Diabetes · doi:10.2337/db11-1462 · Cited by 163
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Insulin Reciprocally Regulates Glucagon Secretion in Humans
Cooperberg, B. A., & Cryer, P. E. (2010) · Diabetes · doi:10.2337/db10-0728 · Cited by 157
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
New hepatic targets for glycaemic control in diabetes
Agius, L. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.001 · Cited by 155
Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives
Rasouli, H., Yarani, R., Pociot, F., & Popović‐Djordjević, J. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104723 · Cited by 153
Lu, J., Herrera, P. L., Carreira, C., Bonnavion, R., Seigne, C., Calender, A., Bertolino, P., & Zhang, C. X. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.046 · Cited by 146
Diabesity: therapeutic options
Colagiuri, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 136
Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery
Swarbrick, M. M., Stanhope, K. L., Austrheim-Smith, I. T., Loan, M. D. V., Ali, M. R., Wolfe, B. M., & Havel, P. J. (2008) · Diabetologia · doi:10.1007/s00125-008-1118-5 · Cited by 136
Metformin and Exercise in Type 2 Diabetes
Boulé, N. G., Robert, C., Bell, G. J., Johnson, S. T., Bell, R. C., Lewanczuk, R. Z., Gabr, R. Q., & Brocks, D. R. (2011) · Diabetes Care · doi:10.2337/dc10-2207 · Cited by 135
Yan, H., Gu, W., Yang, J., Bi, V., Shen, Y., Lee, E. K., Winters, K. A., Komorowski, R., Zhang, C., Patel, J., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147009 · Cited by 135
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2019) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 132
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Ali, S., & Drucker, D. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90887.2008 · Cited by 130
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Mandaliya, D. K., & Seshadri, S. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.021 · Cited by 124
Hellman, B., Salehi, A. A., Gylfe, E., Dansk, H., & Grapengiesser, E. (2009) · Endocrinology · doi:10.1210/en.2009-0600 · Cited by 124
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Cummings, B. P., Digitale, E., Stanhope, K. L., Graham, J. L., Baskin, D. G., Reed, B. J., Sweet, I. R., Griffen, S. C., & Havel, P. J. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90635.2008 · Cited by 123
Jiménez, A., Casamitjana, R., Viaplana-Masclans, J., Lacy, A. M., & Vidal, J. (2013) · Diabetes Care · doi:10.2337/dc12-1535 · Cited by 121
Pfefferkorn, J. A., Guzmán-Pérez, A., Litchfield, J., Aiello, R. J., Treadway, J. L., Pettersen, J. C., Minich, M. L., Filipski, K. J., Jones, C. S., Tu, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2014887 · Cited by 120
The role of GIP in α-cells and glucagon secretion
EL, K. M., & Campbell, J. E. (2019) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 114
Deng, L., Shoji, I., Ogawa, W., Kaneda, S., Soga, T., Jiang, D., Ide, Y.-H., & Hotta, H. (2011) · Journal of Virology · doi:10.1128/jvi.00146-11 · Cited by 113
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
White, M. G., Marshall, H. L., Rigby, R., Huang, G. C., Amer, A. O., Booth, T. A., White, S., & Shaw, J. (2013) · Diabetes Care · doi:10.2337/dc13-0705 · Cited by 110
The RISE Consortium (2013) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 110
Gu, W., Yan, H., Winters, K. A., Komorowski, R., Vonderfecht, S. L., Atangan, L. I., Sivits, G. N., Hill, D., Yang, J., Bi, V., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157685 · Cited by 109
Longevity of human islet α ‐ and β ‐cells
Cnop, M., Igoillo‐Esteve, M., Hughes, S. J., Walker, J. N., Cnop, I., & Clark, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01443.x · Cited by 108
Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 107
Bennet, H., Balhuizen, A., Medina, A., Nitert, M. D., Ottosson-Laakso, E., Essén, S., Spégel, P., Storm, P., Krus, U., Wierup, N., et al. (2015) · Peptides · doi:10.1016/j.peptides.2015.07.008 · Cited by 105
Short- and long-term consequences for offspring exposed to maternal diabetes: a review
Burlina, S., Dalfrà, M. G., & Lapolla, A. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1387893 · Cited by 104
Christensen, M., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3644 · Cited by 104
Glucagon Control on Food Intake and Energy Balance
Al–Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 97
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 97
Inhibitory Effects of Leptin on Pancreatic α-Cell Function
Tudurí, E., Marroquí, L., Soriano, S., Ropero, A. B., Batista, T. M., Piquer, S., López-Boado, M. Á., Carneiro, E. M., Gomis, R., Nadal, Á., et al. (2009) · Diabetes · doi:10.2337/db08-1787 · Cited by 97
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 90
Effects of DPP-4 inhibition on cardiac metabolism and function in mice
Lenski, M., Kazakov, A., Marx, N., Böhm, M., & Laufs, U. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.001 · Cited by 88
Gosmain, Y., Marthinet, E., Cheyssac, C., Guérardel, A., Mamin, A., Katz, L. S., Bouzakri, K., & Philippé, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147215 · Cited by 87
Glucagon secretion and signaling in the development of diabetes
Gaisano, H. Y., MacDonald, P. E., & Vranić, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00349 · Cited by 87
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 86
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kühn, M., Cabrera, O., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-281 · Cited by 86
Quoix, N., Cheng, R., Mattart, L., Zeinoun, Z., Guiot, Y., Beauvois, M. C., Henquin, J., & Gilon, P. (2008) · Diabetes · doi:10.2337/db07-1298 · Cited by 86
Oral Insulin Delivery in a Physiologic Context: Review
Arbit, E., & Kidron, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817691303 · Cited by 83
Cummings, B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson, C., Sams, A. G., Knudsen, L. B., Raun, K., & Havel, P. J. (2010) · Diabetes · doi:10.2337/db09-1564 · Cited by 80
The Somatostatin Receptor in Human Pancreatic β-Cells
Braun, M. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800174-5.00007-7 · Cited by 79
Glucose sensing and the pathogenesis of obesity and type 2 diabetes
Thorens, B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.208 · Cited by 78
Mechanism of insulin resistance in obesity: a role of ATP
Ye, J. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0862-5 · Cited by 77
Andreassen, K. V., Feigh, M., Hjuler, S. T., Gydesen, S., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., Karsdal, M. A., & Henriksen, K. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00121.2014 · Cited by 76
Westwell-Roper, C. Y., Nąckiewicz, D., Dan, M., & Ehses, J. A. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.4 · Cited by 75
Glucagon: acute actions on hepatic metabolism
Miller, R., & Birnbaum, M. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3955-y · Cited by 75
MitoNEET-Parkin Effects in Pancreatic α- and β-Cells, Cellular Survival, and Intrainsular Cross Talk
Kusminski, C. M., Chen, S., Ye, R., Sun, K., Wang, Q. A., Spurgin, S. B., Sanders, P. E., Brozinick, J. T., Geldenhuys, W. J., Li, W.-H., et al. (2016) · Diabetes · doi:10.2337/db15-1323 · Cited by 73
Cairano, E. S. D., Davalli, A. M., Perego, L., Sala, S., Sacchi, V. F., Rosa, S. L., Finzi, G., Placidi, C., Capella, C., Conti, P., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.183517 · Cited by 72
Oral insulin delivery: Barriers, strategies, and formulation approaches: A comprehensive review
Shetty, S., Halagali, P., Johnson, A. P., Spandana, K. M. A., & Gangadharappa, H. V. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125114 · Cited by 70
A Brief Review of the Mechanisms of β-Cell Dedifferentiation in Type 2 Diabetes
Khin, P. P., Lee, J., & Jun, H. (2021) · Nutrients · doi:10.3390/nu13051593 · Cited by 69
The Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 68
The potential role of glutamate in the current diabetes epidemic
Davalli, A. M., Perego, C., & Folli, F. B. (2012) · Acta Diabetologica · doi:10.1007/s00592-011-0364-z · Cited by 64
Kristinsson, H., Sargsyan, E., Manell, H., Smith, D. M., Göpel, S., & Bergsten, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-04730-5 · Cited by 63
Transcriptional regulation of α ‐cell differentiation
Bramswig, N. C., & Kaestner, K. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01440.x · Cited by 62
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 62
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
Moon, J. S., & Won, K. C. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.1.1 · Cited by 61
Habener, J. F., & Stanojevic, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.009 · Cited by 61
Huang, Y., Rupnik, M. S., Karimian, N., Herrera, P. L., Gilon, P., Feng, Z., & Gaisano, H. Y. (2012) · Diabetes · doi:10.2337/db11-0786 · Cited by 61
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale, S. E. (2009) · Frontiers in bioscience · doi:10.2741/3301 · Cited by 60
Rajas, F., Labrune, P., & Mithieux, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.002 · Cited by 60
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 59
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
Kirkpatrick, C. L., Marchetti, P., Purrello, F., Piro, S., Bugliani, M., Bosco, D., de Koning, E. J. P., Engelse, M. A., Kerr-Conte, J. A., Pattou, F. N., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011053 · Cited by 58
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 57
Metadata
- Authors
- Dunning, B. E., & Gerich, J. E.
- Affiliations
- PharmaWrite, Princeton, New Jersey 08540
- University of Rochester Medicine (US)
- Corresponding author
- Gerich, John E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-04-04
- Volume
- 28
- Issue
- 3
- Pages
- 253-283
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2088987697
- Cited by
- 369
- References
- 323
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- University of Rochester
- Kowa Company
- Eisai
- Novo Nordisk
- Medical Center, University of Rochester
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.